2017 Volume 27 Issue 3 Pages 210-216
Recently, drug discovery research for sensorineural hearing loss has gained considerable attention according to progress in research for protection and regeneration of the inner ear. Although sensorineural hearing loss has been known as a common disability, there is no drug that Food and Drug Administration of United States of America. Sudden sensorineural hearing loss is a comparatively rare type of sensorineural hearing loss, while it has several advantages as subjective for clinical trials aiming development of new therapeutics. In this article, recent status of drug discovery research for sensorineural hearing loss and our challenges in research on topical application of insulin-like growth factor-1 for treatment of sudden sensorineural hearing loss are reviewed.
